Natus announces integration of InVisus Pro NMUS into Natus Elite software
The neuromuscular ultrasound (NMUS) option delivered by the latest upgrade to Natus Elite, long considered the gold standard in EMG, expands confidence for healthcare providers using InVisus Pro to confirm and localize pathology. NMUS Integration with one-click reporting also allows clinicians to easily manage the full patient journey.
'The portability, versatility, and high image quality of InVisus makes it perfect as a point-of-care diagnostic tool,' said Dr. Sanjeev Nandedkar, Natus Senior Consultant. 'The integration of InVisus with the familiar environment of Natus Elite software allows seamless use with NCS/EMG testing in routine electrodiagnostic laboratories. The workflow is not altered, and a single report with all test modalities is generated. It also provides additional features such as comparison of results across test modalities and 'on-screen' comparisons with previous investigations. The net result is a better efficiency and better patient care.'
Combining InVisus Pro with Natus Elite makes it simple for doctors and clinicians to compare current and past exams to gain deeper insights. This includes side-by-side, real-time analysis of NMUS and nerve conduction studies (NCS).
Just as doctors benefit from the ability to make quick decisions based on more information, patients find parallel advantages of comfort with a non-invasive testing option and improved patient experience.
ABOUT NATUS
Natus is trusted by healthcare providers around the globe as the solution source to screen, diagnose, and treat disorders affecting the brain and neural pathways. The best-in-class Natus solutions, including service, field support and education, enable clinicians to advance their standard of care, improving patient outcomes and quality of life. For more information on Natus, please visit www.natus.com/neuro.
CONTACT INFORMATION:Lisa SchulerPhone: +1 612 528-1332Email: lisa.schuler@natus.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Balancing Automation with Human Support Key to AI-Driven CX, Says Info-Tech Research Group
Newly released insights from Info-Tech Research Group reveal that over-relying on automation can erode customer trust. To help organizations implement AI without losing the human element, the global IT research and advisory firm has published a step-by-step resource for enhancing customer experience through strategic, outcome-driven AI implementation. TORONTO, July 23, 2025 /CNW/ – Rising service costs, disjointed customer journeys, and growing customer impatience are forcing many organizations to rethink how they scale personalization in customer experience. New research from global research and advisory firm Info-Tech Research Group shows that AI can be transformative for customer experience (CX) when used strategically and intentionally. The firm's studies suggest that meaningful improvements come from balancing automation with human support and aligning technology closely with desired customer outcomes. To support this approach, Info-Tech's recently published resource, Implement AI for Customer Experience, provides a comprehensive framework designed to help organizations improve both customer and employee experiences. Rather than pursuing automation for its own sake, the firm's industry experts encourage CX and IT leaders to use AI to anticipate customer needs, support staff with intelligent tools, and personalize service at scale while maintaining the human touch. 'AI presents an extraordinary opportunity to redefine how organizations connect with their customers, turning routine interactions into high-value experiences that drive loyalty and growth,' says Ryan Brunet, principal research director at Info-Tech Research Group. 'By leveraging advanced capabilities like predictive analytics, sentiment detection, hyperpersonalization, and embedding AI within their contact center, companies can anticipate customer needs, resolve issues proactively, and build lasting brand advocacy.' Info-Tech's insights highlight the challenges organizations face as they strive to balance cost-efficiency with customer satisfaction. The comprehensive resource details that relying too heavily on automation, such as call deflection and fast self-service, can result in shallow customer interactions that ultimately damage trust. To succeed in delivering meaningful, AI-powered customer experiences, the firm's research findings suggest CX and IT leaders track key performance indicators and user feedback in real-time, then refine AI capabilities regularly to stay aligned with shifting customer needs and strategic goals. Brunet, Info-Tech's AI expert and author of the blueprint, notes that 'while AI has the potential to reshape the CX, its success depends on tying efforts to meaningful customer outcomes and ensuring teams are fully prepared to support the transformation.' In its Implement AI for Customer Experience resource, Info-Tech outlines the key advantages of using AI to enhance CX within organizations: Operations Efficiency: Automated tools undertake repetitive tasks such as responding to common inquiries, routing service tickets, and flagging urgent cases. With faster access to relevant customer data, frontline teams can make quicker, more informed decisions. Business Growth: Behavioral analytics and intelligent personalization can reveal customer preferences and anticipate future needs. With these insights, organizations can deliver timely, personalized offers that strengthen retention and unlock new revenue through upselling and cross-selling. Customer Experience: AI systems tailor interactions based on customer history and context, which can enable instant support through chatbots or virtual agents. Faster resolutions and more relevant experiences help build long-term customer loyalty. Employee Experience: By using AI to handle repetitive tasks and deliver real-time insights, employees are able to focus on complex issues that require human judgment. This shift can reduce stress, boost engagement, and improve overall performance among staff. Risk and Resilience: With early issue detection and proactive responses, AI can help organizations manage disruptions, while data-backed strategies build adaptable, future-ready service models. 'The future is bright for CX leaders who fully embrace the transformative potential of AI,' explains Brunet. 'With the right strategic alignment, AI becomes more than a piece of the technology puzzle; it becomes the catalyst for deeper engagement, stronger loyalty, and sustainable growth.' For exclusive and timely commentary from Ryan Brunet, an expert in AI and data science applications, and access to the complete Implement AI for Customer Experience blueprint, please contact pr@ Info-Tech's Upcoming Webinar on AI Strategies for Customer Experience To further explore the strategies outlined in the new research, Info-Tech Research Group will host a webinar, Adapt to Uncertainty With an IT Resilience Plan, on August 6, 2025, at 1:00 p.m. EDT. This webinar will equip IT leaders with actionable strategies to improve customer experience outcomes using AI and propel their brand forward while building resilience in a rapidly changing landscape. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@ For information about Info-Tech Research Group or to access the latest research, visit and connect via LinkedIn and X.
Malaysian Reserve
16 hours ago
- Malaysian Reserve
D2L Announces Createspace to Help Simplify Course Creation with Real-Time Collaboration
More innovative D2L Brightspace features announced alongside all-new D2L Academy and exciting H5P updates SAVANNAH, Ga., July 22, 2025 /CNW/ – D2L, a global leader in learning innovation, today announced during its annual Fusion user conference the launch of its all-new Createspace, the next generation of authoring and content management—now available in beta for all Creator+ users. Createspace allows educators and course authors to create, edit, and collaborate on content with intuitive tools in a dedicated space before publishing it to learners. Createspace is set to be generally available to all D2L Brightspace users later this year. 'Inspired and informed by our work on Creator+, we are proud to introduce Createspace to help transform authoring and content management within D2L Brightspace,' said Christian Pantel, Chief Product Officer at D2L. 'By giving educators a collaborative space to create and manage content more efficiently all in one place, we are helping them save time, reduce complexity, and focus on what matters most: reaching and engaging learners.' New Capabilities D2L also launched a suite of additional features to its core D2L Brightspace learning platform. The latest updates are designed to help educators and learners get even more out of their platform and deliver improved upskilling outcomes. The new D2L Brightspace offerings include: Enhancements to Assessments, allowing instructors to quickly reopen quiz attempts, deliver feedback in bulk, and use quiz filters to help analyze results and make grading faster. Expanded group enrollment capacity, increasing the group size limit from 200 to 3,000 learners, and providing educators with more enhanced filters to tailor groups. Improved visibility for Parents and Guardians by allowing educators to communicate more effectively through the class list, announcements, and templated emails. Updates to employee learning with a flexible UX design that can empower organizations to deliver structured, repeatable learning at scale–equipped with progress tracking, prerequisites, and integration with HR systems. Print Quiz helps educators increase quiz value and accessibility for learners. 'With the latest enhancements to D2L Brightspace, we are giving educators even more powerful tools to help unlock the full potential of learners,' said John Baker, President, Founder and CEO of D2L. 'From expanding group capacity to launching Print Quiz and improving assessment workflows, we're making it easier for educators to deliver highly accessible, future-ready education at scale. By helping to empower learning leaders with innovative tools, we are not just breaking barriers—we are helping to build a future where all learners can thrive.' Announcing D2L Academy D2L also announced the launch of D2L Academy, a centralized hub for D2L learning resources to help educators and leaders unlock the full potential of D2L Brightspace. D2L Academy provides access to a comprehensive suite of training material, including more than 40 courses, expert-led live sessions, industry-recognized certifications and support for configuring D2L Brightspace, specifically designed to help empower educators, learning leaders and course administrators. Enhancements to H5P New enhancements to H5P to refresh the user experience, providing users with a more intuitive way to build and interact with engaging content – including: Smart Import powered by generative AI expands to support 56 languages. A visual, drag-and-drop editing experience to better combine text and multimedia content. Enhanced accessibility with new ARIA roles and improved keyboard navigation. Newly redesigned native integration into D2L Creator+. Explore the D2L product roadmap to learn more about upcoming releases, updates, and features. About D2L D2L is transforming the way the world learns, helping learners achieve more than they dreamed possible. Working closely with customers all over the world, D2L is on a mission to make learning more inspiring, engaging and human. Find out how D2L helps transform lives and delivers outstanding learning outcomes in K-12, higher education and business at The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L Asia Pte Ltd, D2L India Pvt Ltd, D2L Brasil Soluções de Tecnologia para Educação Ltda and D2L Sistemas de Aprendizaje Innovadores, S. D2 R.L de C.V., and H5P Group AS. All D2L and H5P marks are owned by the D2L group of companies. Please visit for a list of D2L marks. All other trademarks are the property of their respective owners.
Malaysian Reserve
a day ago
- Malaysian Reserve
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
– In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to TRIKAFTA – – Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time – TORONTO, July 22, 2025 /CNW/ – Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in Canada who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK may also provide a new treatment option and flexibility for approximately 3,800 people given the need to take CFTR modulators with fat-containing food. 'ALYFTREK represents the next generation of CFTR modulator treatment and is a testament to our long-standing goal to address the underlying cause of cystic fibrosis, treat more people living with CF, and bring more people to normal levels of CFTR function,' said Michael Siauw, General Manager at Vertex Pharmaceuticals (Canada) Incorporated. 'With once-daily dosing, eligibility in 113 additional mutations, and the potential to lower sweat chloride levels even further, ALYFTREK brings us one step closer to achieving this goal.' This approval is based on a comprehensive Phase 3 pivotal program, including more than 1,000 patients across more than 20 countries and more than 200 sites. The Phase 3 studies in people with CF ages 12 years and older met their primary endpoint (non-inferiority on absolute change from baseline in ppFEV1 compared to TRIKAFTA) and all key secondary endpoints (including absolute change from baseline in sweat chloride [SwCl] compared to TRIKAFTA). In the Phase 3 study of children with CF ages 6-11 years, ALYFTREK demonstrated safety, the primary endpoint. Secondary endpoints, such as absolute change from baseline in ppFEV1 and absolute change from baseline in SwCl, demonstrate the benefit of ALYFTREK in this age group. ALYFTREK was generally well tolerated across all studies. 'For Canadian patients and families, the approval of ALYFTREK represents significant progress towards improved care,' said Dr. Bradley Quon, Medical and Research Director of the Adult Cystic Fibrosis Program at St. Paul's Hospital, and Associate Professor of Medicine in the Faculty of Medicine at the University of British Columbia. 'Lower levels of sweat chloride combined with the convenience of a once-a-day treatment provides a new option that has the potential to both improve CFTR function and reduce treatment burden.' ALYFTREK is currently approved in the U.S., UK and European Union and is under regulatory review in Switzerland, Australia and New Zealand. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. Sweat chloride, which measures CFTR function, is used to diagnose CF. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of a CFTR gene mutation but do not have any manifestation of disease (carriers). At a population level, higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. Restoring SwCl levels below 30 mmol/L has long been the ultimate treatment goal for Vertex, as levels below 30 mmol/L are considered normal and are typical of CF carriers who do not have disease. About ALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor) In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane. ALYFTREK is approved in the U.S., UK, and Canada for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. ALYFTREK is approved in the European Union for the treatment of CF in patients ages 6 years and older who have at least one non-class I mutation in the CFTR gene. Boxed Warning Elevated transaminases have been observed in some patients treated with ALYFTREK. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking a fixed dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains one same (tezacaftor) and one similar (ivacaftor) active ingredient as ALYFTREK. Liver injury has primarily been reported within the first 6 months following initiation of elexacaftor/tezacaftor/ivacaftor. See full ALYFTREK Product Monograph for further details. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Michael Siauw and Dr. Bradley Quon, and statements regarding the anticipated eligible patient population in Canada and expectations for the ALYFTREK regulatory submissions in Switzerland, Australia and New Zealand. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex Pharmaceuticals IncorporatedInvestors:InvestorInfo@ Media: mediainfo@ +1 647-790-1600
